Provided by Tiger Trade Technology Pte. Ltd.

Tango Therapeutics Inc.

23.37
-0.6300-2.62%
Post-market: 23.370.00000.00%19:30 EDT
Volume:3.44M
Turnover:81.01M
Market Cap:3.95B
PE:-27.82
High:24.30
Open:23.16
Low:23.16
Close:24.00
52wk High:34.39
52wk Low:6.32
Shares:169.00M
Float Shares:142.96M
Volume Ratio:1.46
T/O Rate:2.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8400
EPS(LYR):-0.8746
ROE:-21.34%
ROA:-12.99%
PB:3.85
PE(LYR):-26.72

Loading ...

Aug 30, 2023

Major Issues Report

Form 8-K - Current report
Aug 22, 2023

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Aug 17, 2023

Beneficial Ownership Change

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
Aug 10, 2023

Major Issues Report

Form 8-K - Current report
Aug 07, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 07, 2023

Major Issues Report

Form 8-K - Current report
Jun 07, 2023

Major Issues Report

Form 8-K - Current report
May 09, 2023

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
May 09, 2023

Major Issues Report

8-K - Current report
Mar 27, 2023

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 27, 2023

Major Issues Report

8-K - Current report
Feb 28, 2023

Major Issues Report

8-K - Current report
Feb 14, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 14, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 07, 2023

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Nov 10, 2022

Major Issues Report

8-K - Current report
Nov 10, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Sep 08, 2022

Correspondence

CORRESP [Cover] - Correspondence
Aug 10, 2022

Major Issues Report

8-K - Current report
Aug 10, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]